MiroBio who are a leader in the development of checkpoint agonists to treat autoimmune diseases, have announced on Wednesday the completion of a $97m (£80m) Series B financing led by…
The post MiroBio raises $97m Series B financing to develop checkpoint agonists for treatment of autoimmune diseases appeared first on London Business News | Londonlovesbusiness.com.